Tuesday, July 25, 2017 1:44:00 PM
Hey antihama,
the korean phase II breast cancer data we will see at ESMO must be good or very good.
EXEL first had a proffered poster presentation last year with their CaboSun Study. They even got promoted to a presidential session because the data was practice changing. They showed that their drug is significantly better than the first line treatment in RCC sunitinib.
So i expect SPPI to go higher from here - technical breakout above USD 8.
If you know me back from the Yahoo message board you know i am not a fan of Raj, the ultimative pusher, but with poziotinib he may be onto something this time. In NSCLC and BC.
We will get a dilution soon, but with rolontis and poziotinib much better years could be ahead.
Ville
Recent SPPI News
- Form 15-12G - Securities registration termination [Section 12(g)] • Edgar (US Regulatory) • 11/09/2023 10:00:17 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 09/28/2023 04:15:27 AM
- Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments • Edgar (US Regulatory) • 09/26/2023 09:23:08 PM
FEATURED Element79 Gold Corp Successfully Closes Maverick Springs Option Agreement • May 8, 2024 9:05 AM
Bantec's Howco Awarded $4.19 Million Dollar U.S. Department of Defense Contract • BANT • May 8, 2024 10:00 AM
Kona Gold Beverages, Inc. Achieves April Revenues Exceeding $586,000 • KGKG • May 8, 2024 8:30 AM
Epazz plans to spin off Galaxy Batteries Inc. • EPAZ • May 8, 2024 7:05 AM
Moon Equity Holdings, Corp. Announces Acquisition of Wikolo, Inc. • MONI • May 7, 2024 9:48 AM
Cannabix Technologies Launches New Compact Breath Logix Workplace Series and Prepares for Delivery to South Africa • BLOZF • May 7, 2024 8:51 AM